Berenson GS, Srinivasan SR, Hunter SM, Nicklas TA, Freedman DS, Shear CL, et al. Risk factors in early life as predictors of adult heart disease: the Bogalusa Heart Study. Am J Med Sci. 1989;298(3):141–51. https://doi.org/10.1097/00000441-198909000-00001.

Article  CAS  PubMed  Google Scholar 

Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. Lancet. 9943;384(9943):626–35. https://doi.org/10.1016/s0140-6736(14)61177-6.

Article  Google Scholar 

Zhang H, Zhou XD, Shapiro MD, Lip GYH, Tilg H, Valenti L, et al. Global burden of metabolic diseases, 1990–2021. Metabolism. 1990;160:155999, 155999. https://doi.org/10.1016/j.metabol.2024.155999.

Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health. 2022;6(3):158–70. https://doi.org/10.1016/s2352-4642(21)00374-6.

Article  PubMed  Google Scholar 

Chong B, Kong G, Shankar K, Chew HSJ, Lin C, Goh R, et al. The global syndemic of metabolic diseases in the young adult population: a consortium of trends and projections from the Global Burden of Disease 2000–2019. Metabolism. 2000;141:155402, 155402. https://doi.org/10.1016/j.metabol.2023.155402.

Martino F, Niglio T, Martino E, Paravati V, de Sanctis L, Guardamagna O. Apolipoprotein B and lipid profile in Italian children and adolescents. J Cardiovasc Dev Dis. 2024. https://doi.org/10.3390/jcdd11020044.

Article  PubMed  PubMed Central  Google Scholar 

Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):785–812. https://doi.org/10.1016/s0140-6736(25)00397-6.

Kavey RW. Combined Dyslipidemia in Children and Adolescents: a Proposed New Management Approach. Curr Atheroscler Rep. 2023;25(5):237–45. https://doi.org/10.1007/s11883-023-01099-x.

Article  PubMed  Google Scholar 

Raitakari O, Kartiosuo N, Pahkala K, Hutri-Kähönen N, Bazzano LA, Chen W, et al. Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood. Circulation. 2023;147(1):23–31. https://doi.org/10.1161/circulationaha.122.060667.

Article  CAS  PubMed  Google Scholar 

Poznyak AV, Yakovlev AA, Popov M, Zhigmitova EB, Sukhorukov VN, Orekhov AN. Atherosclerosis originating from childhood: specific features. J Biomed Res. 2024;38(3):233–40. https://doi.org/10.7555/jbr.37.20230198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stary HC. Lipid and macrophage accumulations in arteries of children and the development of atherosclerosis. Am J Clin Nutr. 2000;72:1297s–306s. https://doi.org/10.1093/ajcn/72.5.1297s.

Article  CAS  PubMed  Google Scholar 

Almohtasib Y, Fancher AJ, Sawalha K. Emerging trends in atherosclerosis: time to address atherosclerosis from a younger age. Cureus. 2024;16(3):e56635. https://doi.org/10.7759/cureus.56635.

Article  PubMed  PubMed Central  Google Scholar 

Takaoka M, Zhao X, Lim HY, Magnussen CG, Ang O, Suffee N, et al. Early intermittent hyperlipidaemia alters tissue macrophages to fuel atherosclerosis. Nature. 8033;634(8033):457–65. https://doi.org/10.1038/s41586-024-07993-x.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;139(25):e1046–81. https://doi.org/10.1161/cir.0000000000000624.

Article  PubMed  Google Scholar 

Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359–78. https://doi.org/10.1093/eurheartj/ehaf190.

Article  CAS  PubMed  Google Scholar 

Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol. 2023;14:1190934, 1190934. https://doi.org/10.3389/fphar.2023.1190934.

Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34(45):3478. https://doi.org/10.1093/eurheartj/eht273.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldstein JL, Brown MS. The LDL receptor and the regulation of cellular cholesterol metabolism. J Cell Sci Suppl. 1985;3:131–7. https://doi.org/10.1242/jcs.1985.supplement_3.13.

Article  CAS  PubMed  Google Scholar 

Soria LF, Ludwig EH, Clarke HR, Vega GL, Grundy SM, McCarthy BJ. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci U S A. 1989;86(2):587–91. https://doi.org/10.1073/pnas.86.2.587.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abifadel M, Varret M, Rabès JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34(2):154–6. https://doi.org/10.1038/ng1161.

Article  CAS  PubMed  Google Scholar 

Ganesan D, Bass HB, McConathy WJ, Alaupovic P. Is decreased activity of C-II activated lipoprotein lipase in type III hyperlipoproteinemia (broad-β-disease) a cause or an effect of increased apolipoprotein E levels? Metabolism. 1976;25(11):1189–95. https://doi.org/10.1016/s0026-0495(76)80001-7.

Article  CAS  PubMed  Google Scholar 

Haubenwallner S, Hörl G, Shachter NS, Presta E, Fried SK, Höfler G, et al. A novel missense mutation in the gene for lipoprotein lipase resulting in a highly conservative amino acid substitution (Asp180–>Glu) causes familial chylomicronemia (type I hyperlipoproteinemia). Genomics. 1993;18(2):392–6. https://doi.org/10.1006/geno.1993.1481.

Article  CAS  PubMed  Google Scholar 

Cruz-Bautista I, Huerta-Chagoya A, Moreno-Macías H, Rodríguez-Guillén R, Ordóñez-Sánchez ML, Segura-Kato Y, et al. Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia. Lipids Health Dis. 2021;20(1):14, 14. https://doi.org/10.1186/s12944-021-01436-6.

Bea AM, Cenarro A, Marco-Bened V, Laclaustra M, Martn C, Ibarretxe D, et al. Diagnosis of Familial Dysbetalipoproteinemia Based on the Lipid Abnormalities Driven by APOE2/E2 Genotype. Clin Chem. 2023;69(2):140–8. https://doi.org/10.1093/clinchem/hvac213.

Article  CAS  PubMed  Google Scholar 

Altmann SW, Davis HR Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G, et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 5661;303(5661):1201–4. https://doi.org/10.1126/science.1093131.

Article  CAS  Google Scholar 

Hair P, Cameron F, McKeage K. Mipomersen sodium: first global approval. Drugs. 2013;73(5):487–93. https://doi.org/10.1007/s40265-013-0042-2.

Article  CAS  PubMed  Google Scholar 

Santos RD, Wiegman A, Caprio S, Cariou B, Averna M, Poulouin Y, et al. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA Pediatr. 2024;178(3):283–93. https://doi.org/10.1001/jamapediatrics.2023.6477.

Article  PubMed  PubMed Central  Google Scholar 

Sparks DL, Pritchard PH. Transfer of cholesteryl ester into high density lipoprotein by cholesteryl ester transfer protein: effect of HDL lipid and apoprotein content. J Lipid Res. 1989;30(10):1491–8.

Article  CAS  PubMed  Google Scholar 

Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, et al. Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med. 2017;377(13):1217–27. https://doi.org/10.1056/NEJMoa1706444.

Article  PubMed  Google Scholar 

Chen YQ, Zhao SP, Ye HJ. Efficacy and safety of coenzyme A versus fenofibrate in patients with hyperlipidemia: a multicenter, double-blind, double-mimic, randomized clinical trial. Curr Med Res Opin. 2020;36(6):941–5. https://doi.org/10.1080/03007995.2020.1747416.

Article  CAS  PubMed  Google Scholar 

Shimizugawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem. 2002;277(37):33742–8. https://doi.org/10.1074/jbc.M203215200.

Article  CAS  PubMed  Google Scholar 

Wiegman A, Greber-Platzer S, Ali S, Reijman MD, Brinton EA, Charng MJ, et al. Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia. Circulation. 2024;149(5):343–53. https://doi.org/10.1161/circulationaha.123.065529.

Article  CAS